Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary CD103+ dendritic cells are critical for cross‐presentation of tumor antigens. Here we have shown that during immunotherapy, large numbers of cells expressing CD103 arose in murine tumors via direct differentiation of Ly6c+ monocytic precursors. These Ly6c+CD103+ cells could derive from bone‐marrow monocytic progenitors (cMoPs) or from peripheral cells present within the myeloid‐derived suppressor cell (MDSC) population. Differentiation was controlled by inflammation‐induced activation of the transcription factor p53, which drove upregulation of Batf3 and acquisition of the Ly6c+CD103+ phenotype. Mice with a targeted deletion of p53 in myeloid cells selectively lost the Ly6c+CD103+ population and became unable to respond to multiple forms of immunotherapy and immunogenic chemotherapy. Conversely, increasing p53 expression using a p53‐agonist drug caused a sustained increase in Ly6c+CD103+ cells in tumors during immunotherapy, which markedly enhanced the efficacy and duration of response. Thus, p53‐driven differentiation of Ly6c+CD103+ monocytic cells represents a potent and previously unrecognized target for immunotherapy. Graphical Abstract Figure. No Caption available. HighlightsDuring tumor immunotherapy, CD103+ APCs can arise from the myeloid lineageThese CD11c+CD103+ APCs are Batf3 dependent but co‐express monocytic markersDifferentiation of these cells from immature MDSC precursors is controlled by p53Selective ablation of this population results in profound defects in tumor immunity &NA; Conventional CD103+ DCs are critical APCs for cross‐presentation of tumor antigens. Sharma and colleagues show that a potent population of Batf3‐dependent, CD103+ cross‐presenting APCs can arise during tumor immunotherapy via direct differentiation of immature monocytic precursors present in the peripheral MDSC pool.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 3×
“The ability to elicit immunogenic antigen presentation in tumors is a key determinant of effective cancer immunotherapy (Chen and Mellman, 2013).”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Systemic treatment with the prototypical MDM2-inhibitor nutlin-3a (Vassilev et al., 2004) caused a 2- to 3-fold increase in mean fluorescence intensity of p53 staining in these high-expressing cells, specifically including Ly6c+ myeloid cells.”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“ICD is known to be driven by inflammatory signals such as TLR4andATP receptors (Apetoh et al., 2007; Ghiringhelli et al., 2009), and the Ly6c+CD103+ cells proved to be themain cells that expressed these receptors following oxaliplatin treatment (Figure S4F).”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 2×
“While these conventional CD103+ DCs can be present in tumors, they are often limited in number, and many tumors appear to actively exclude them (Spranger et al., 2015).”
BackgroundBatf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · cited 5×
“Batf3-deficient mice lack critical antigen-presenting activity required for anti-tumor immunity (Hildner et al., 2008).”
BackgroundResultInfluentialGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 4×
“Similarly, the Lyz2cre-Trp53flox/flox mice lost all response to a model of chemotherapy-induced immunogenic cell death (ICD) (Ghiringhelli et al., 2009), comprising E.G7 tumors treatedwith oxaliplatin (Figure S4E).”
BackgroundInfluentialExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Marino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Cited by
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Monocyte heterogeneity and functions in cancer
Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0818-311r · Cited by 579
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
Dendritic Cells and Their Role in Immunotherapy
Gardner, A., de Mingo Pulido, Á., & Ruffell, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00924 · Cited by 485
Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372
“Notably, some reports demonstrate that under specific therapeutic settings, DC subsets distinct from DC1s can become robust CD8 T cell activators (Ma et al., 2013; Sharma et al., 2018).”
Backgroundp53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
“As a result, deletion of p53 in these IMPs accelerates subcutaneous tumour growth due to a lack of tumour-associated APCs and, consequently, reduces T cell activation (Sharma et al., 2018) (Fig.”
BackgroundMonocytes in the Tumor Microenvironment
Ugel, S., Canè, S., De Sanctis, F., & Bronte, V. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 314
Self-citationXiao, Y., Chen, J., Zhou, H., Zeng, X., Ruan, Z., Pu, Z., Jiang, X., Matsui, A., Zhu, L., Amoozgar, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28279-8 · Cited by 264
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
Munn, D. H., Sharma, M. D., & Johnson, T. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1351 · Cited by 84
Self-citation
Metadata
- Authors
- Sharma, M. D., Rodriguez, P. C., Koehn, B. H., Baban, B., Cui, Y., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., Xu, H., Johnson, T. S., He, Y., Mergoub, T., Venable, C., Bronte, V., Wolchok, J. D., Blazar, B. R., & Munn, D. H.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 48
- Issue
- 1
- Pages
- 91-106.e6
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2783617985
- Cited by
- 119
- References
- 11
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.